About: Aprotinin

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Aprotinin Goto Sponge NotDistinct Permalink

An Entity of Type : http://linked.opendata.cz/ontology/drugbank/Drug, within Data Space : linked.opendata.cz associated with source document(s)

Attributes	Values
rdf:type	http://linked.opendata.cz/ontology/drugbank/Drug
http://linked.open...gbank/description	Aprotinin, also known as bovine pancreatic trypsin inhibitor, BPTI (Trasylol, Bayer) is a protein, that is used as medication administered by injection to reduce bleeding during complex surgery, such as heart and liver surgery. Its main effect is the slowing down of fibrinolysis, the process that leads to the breakdown of blood clots. The aim in its use is to decrease the need for blood transfusions during surgery, as well as end-organ damage due to hypotension (low blood pressure) as a result of marked blood loss. The drug was temporarily withdrawn worldwide in 2007 after studies suggested that its use increased the risk of complications or death; after this was confirmed by follow-up studies, Trasylol was entirely and permanently withdrawn in May 2008, except - at least for the time being - for very restricted research use. [Wikipedia] (en)
http://linked.open...generalReferences	# Mahdy AM, Webster NR: Perioperative systemic haemostatic agents. Br J Anaesth. 2004 Dec;93(6):842-58. Epub 2004 Jul 26. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/15277296 (en)
http://linked.open...gy/drugbank/group	approved (en) withdrawn (en)
http://linked.open...drugbank/halfLife	Following this distribution phase, a plasma half-life of about 150 minutes is observed. At later time points, (i.e., beyond 5 hours after dosing) there is a terminal elimination phase with a half-life of about 10 hours. (en)
http://linked.open...ugbank/indication	For prophylactic use to reduce perioperative blood loss and the need for blood transfusion in patients undergoing cardiopulmonary bypass in the course of coronary artery bypass graft surgery who are at an increased risk for blood loss and blood transfusion. (en)
sameAs	Aprotinin Aprotinin
Title	Aprotinin (en)
adms:identifier	http://linked.opendata.cz/resource/drugbank/drug/DB06692/identifier/drugbank/DB06692 http://linked.opendata.cz/resource/drugbank/drug/DB06692/identifier/national-drug-code-directory/0026-8196-36 http://linked.opendata.cz/resource/drugbank/drug/DB06692/identifier/pharmgkb/PA448472 http://linked.opendata.cz/resource/drugbank/drug/DB06692/identifier/kegg-drug/D02971 http://linked.opendata.cz/resource/drugbank/drug/DB06692/identifier/wikipedia/Aprotinin
http://linked.open...mechanismOfAction	Aprotinin inhibits several serine proteases, specifically trypsin, chymotrypsin and plasmin at a concentration of about 125,000 IU/ml, and kallikrein at 300,000 IU/ml. Its action on kallikrein leads to the inhibition of the formation of factor XIIa. As a result, both the intrinsic pathway of coagulation and fibrinolysis are inhibited. Its action on plasmin independently slows fibrinolysis. (en)
http://linked.open...drugbank/packager	Baxter International Inc. Bayer Healthcare
http://linked.open...outeOfElimination	Following a single IV dose of radiolabelled aprotinin, approximately 25-40% of the radioactivity is excreted in the urine over 48 hours. After a 30 minute infusion of 1 million KIU, about 2% is excreted as unchanged drug. After a larger dose of 2 million KIU infused over 30 minutes, urinary excretion of unchanged aprotinin accounts for approximately 9% of the dose. (en)
http://linked.open.../drugbank/synonym	BPTI (en) Iniprol (en) Trazinin (en) bovine pancreatic trypsin inhibitor (en)
http://linked.open.../drug/hasAHFSCode	http://linked.opendata.cz/resource/AHFS/20-28-16
http://linked.open.../drugbank/mixture	Multi Vitamin-Mineral Formula Multi-Vitamin Dietary Supplement Mycelized Childrens Multi-Vitamin Liq
http://linked.open...ynthesisReference	Marion Steinbuch, Jacques Chabbat, Olivier Taby, "Process for preparation of activated protein C by immobilized aprotinin chromatography." U.S. Patent US5198534, issued February, 1985. (en)
http://linked.open...y/mesh/hasConcept	http://linked.opendata.cz/resource/mesh/concept/M0011905
foaf:page	http://www.drugs.com/cdi/aprotinin.html http://www.rxlist.com/trasylol-drug.htm
http://linked.open...Molecular-Formula	http://linked.opendata.cz/resource/drugbank/property/271B4E72-363D-11E5-9242-09173F13E4C5
http://linked.open.../Molecular-Weight	http://linked.opendata.cz/resource/drugbank/property/271B4E71-363D-11E5-9242-09173F13E4C5
http://linked.open...l/drug/hasATCCode	Aprotinin
http://linked.open...ugbank/absorption	100% (IV) (en)
http://linked.open.../affectedOrganism	Humans and other mammals (en)
http://linked.open...casRegistryNumber	9087-70-1 (en)
http://linked.open...drugbank/category	(en)
http://linked.open...ank/Melting-Point	http://linked.opendata.cz/resource/drugbank/property/271B4E70-363D-11E5-9242-09173F13E4C5

Faceted Search & Find service v1.16.118 as of Jun 21 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3240 as of Jun 21 2024, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (126 GB total memory, 46 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software